Capital Square’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.23M Sell
4,780
-772
-14% -$783K 1.95% 7
2025
Q4
$5.97M Sell
5,552
-68
-1% -$65K 3.04% 3
2025
Q3
$4.29M Sell
5,620
-77
-1% -$57.3K 2.19% 5
2025
Q2
$4.52M Buy
5,697
+508
+10% +$395K 2.41% 4
2025
Q1
$4.29M Buy
5,189
+115
+2% +$95.7K 2.52% 3
2024
Q4
$3.99M Buy
5,074
+14
+0.3% +$11.6K 2.26% 4
2024
Q3
$4.48M Sell
5,060
-192
-4% -$173K 2.72% 3
2024
Q2
$4.55M Buy
5,252
+326
+7% +$261K 2.96% 3
2024
Q1
$3.83M Buy
4,926
+131
+3% +$93.2K 2.71% 3
2023
Q4
$2.8M Buy
4,795
+408
+9% +$238K 3.16% 4
2023
Q3
$2.66M Sell
4,387
-4
-0.1% -$2.06K 3.59% 3
2023
Q2
$2.06M Sell
4,391
-48
-1% -$20.1K 1.91% 12
2023
Q1
$1.64M Sell
4,439
-35
-0.8% -$11.8K 1.51% 17
2022
Q4
$1.64M Sell
4,474
-33
-0.7% -$11.7K 1.48% 18
2022
Q3
$1.46M Buy
4,507
+225
+5% +$71.3K 1.32% 21
2022
Q2
$1.39M Sell
4,282
-9
-0.2% -$2.7K 1.15% 23
2022
Q1
$1.23M Sell
4,291
-8
-0.2% -$2.06K 0.88% 37
2021
Q4
$1.12M Buy
4,299
+8
+0.2% +$2.03K 0.77% 41
2021
Q3
$985K Buy
4,291
+3
+0.1% +$740 0.7% 46
2021
Q2
$1.02M Sell
4,288
-2
-0% -$402 0.75% 44
2021
Q1
$791K Buy
4,290
+27
+0.6% +$5.28K 0.59% 57
2020
Q4
$719K Buy
4,263
+18
+0.4% +$2.69K 0.6% 56
2020
Q3
$628K Buy
4,245
+67
+2% +$10.4K 0.65% 52
2020
Q2
$686K Sell
4,178
-217
-5% -$33.3K 0.73% 41
2020
Q1
$610K Sell
4,395
-213
-5% -$29.3K 0.71% 38
2019
Q4
$605K Buy
+4,608
New +$534K 0.58% 50

Other funds holding LLY

Capital Square's LLY Position: Q1 2026 in Review

Capital Square reduced its Eli Lilly (LLY) stake by 14% in Q1 2026, selling an estimated $783K and leaving 4,780 shares worth $4.23M. The position accounts for 1.95% of the portfolio, ranked #7.

Capital Square first reported a position in LLY in Q4 2019 and has held it in 26 quarters since. The position peaked at $5.97M in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Capital Square held 4,780 shares of Eli Lilly worth $4.23M as of Q1 2026.
  • Capital Square sold 772 Eli Lilly shares in Q1 2026, an estimated $783K.
  • Eli Lilly made up 1.95% of Capital Square's portfolio in Q1 2026, its #7 holding.
  • Capital Square first reported a position in Eli Lilly in Q4 2019 and has held it in 26 quarters since.
  • Capital Square's Eli Lilly position peaked at $5.97M in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Capital Square's 13F filing for Q1 2026, filed 11 May 2026.